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Background and Purpose—Perturbations in cerebral microcirculation (eg, microvasospasms) and reduced neurovascular 
communication determine outcome after subarachnoid hemorrhage (SAH). ET-1 (endothelin-1) and its receptors have 
been implicated in the pathophysiology of large artery spasms after SAH; however, their role in the development of 
microvascular dysfunction is currently unknown. Here, we investigated whether inhibiting ET
A
 (endothelin A) receptors 
can reduce microvasospasms after experimentally induced SAH.
Methods—SAH was induced in male C57BL/6 mice by filament perforation of the middle cerebral artery. Three hours after 
SAH, a cranial window was prepared and the pial and parenchymal cerebral microcirculation was measured in vivo using 
two-photon microscopy before, during, and after administration of the ET
A
 receptor inhibitor clazosentan. In separate 
experiments, the effect of clazosentan treatment on neurological outcome was measured 3 days after SAH.
Results—Clazosentan treatment had no effect on the number or severity of SAH-induced cerebral microvasospasms nor did 
it affect neurological outcome.
Conclusions—Our results indicate that ET
A
 receptors, which mediate large artery spasms after SAH, do not seem to play 
a role in the development of microarterial spasms, suggesting that posthemorrhagic spasms are mediated by distinct 
mechanisms in large and small cerebral vessels. Given that cerebral microvessel dysfunction is a key factor for outcome 
after SAH, further research into the mechanisms that underlie posthemorrhagic microvasospasms is urgently needed.
Visual Overview—An online visual overview is available for this article.   (Stroke. 2018;49:693-699. DOI: 10.1161/
STROKEAHA.117.020028.)
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Subarachnoid hemorrhage (SAH) is a devastating sub-type of stroke most commonly caused by the rupture of 
a cerebral aneurysm. SAH predominantly occurs in relatively 
younger (ie, 40–60 years) patients and often leaves the sur-
vivor severely disabled. Strikingly, SAH incurs nearly the 
same socioeconomic cost as ischemic stroke, which affects 
20× as many patients. Although early post-SAH mortality (ie, 
within the first 24 hours after the insult) has declined in recent 
decades because of improved emergency and surgical care, 
the 30-day mortality rate is still high.1–4 Moreover, the cause of 
death of these closely monitored—and in many cases, appar-
ently stable—patients is often unknown.
Poor outcome after SAH, including delayed mortality, is 
associated with delayed ischemic neurological deficits, which 
often cause secondary infarcts. For decades, delayed vaso-
spasms of large arteries located primarily within the circle 
of Willis were thought to underlie the delayed ischemia and 
poor outcome after SAH. Moreover, a vast amount of research 
revealed that the vascular endothelin receptor subtype ET
A
 
(endothelin A) is a primary contributor to posthemorrhagic 
large artery spasms.5–11 However, although recent clinical tri-
als showed that the ET
A
 receptor antagonist clazosentan can 
resolve large artery spasms, it did not improve patient out-
come.12,13 Therefore, these results raised doubts on whether 
large artery spasms indeed underlie the delayed ischemia 
after SAH.
In search for other mechanisms that underlie post-SAH 
ischemia and determine clinical outcome, researchers 
observed that despite normal cerebral perfusion pressure and 
the absence of large artery spasms, patients developed cerebral 
hypoperfusion within the first few days after SAH.14,15 This 
paradoxical finding was also observed in animals after experi-
mental SAH16 and was associated with microvasospasms17 
that resulted in oligemia and lipid peroxidation,16,18 ultimately 
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leading to microvascular thrombosis19 and complete loss of 
microvascular perfusion. Therefore, determining precisely 
why microvasospasms occur after SAH might provide a novel 
therapeutic strategy for improving tissue perfusion in these 
patients. However, the mechanisms that underlie the develop-
ment of microvasospasms after SAH are largely unknown.
Here, we investigated whether inhibiting ET
A
 receptors—a 
strategy that can resolve large artery spasms after SAH—may 
also be effective in reducing cerebral microvasospasms after 
experimental SAH, providing a possible therapeutic strategy 
for preventing post-SAH cerebral microvasospasms. For this 
purpose, we chose a mouse model that reproduces the main 
features of early brain injury, early mortality, marked micro-
circulatory hypoperfusion, and microvasospasm.
Materials and Methods
The authors declare that all supporting data are available within the 
article (and its online-only Data Supplement). All animal procedures, 
group size calculations, and statistical methods used were approved 
by the Government of Upper Bavaria (AZ#66-08). Sample size 
was calculated using SigmaPlot v13.0 (Jandel Scientific, Erkrath, 
Germany). The results of the study are reported in accordance with 
the ARRIVE guidelines. Given the relevant differences between gen-
ders with respect to stroke pathophysiology, and given that this study 
was intended to provide proof-of-principle rather than therapeutic 
intent, we used only male animals, thereby ensuring comparability 
of our results with previous studies performed using the same setup, 
model, and drug regimen.
Randomization and Blinding
After the induction of SAH, animals were randomly assigned to 
either the treatment or the control group by drawing lots. Where 
appropriate, the surgical preparation for SAH was performed in a 
blinded fashion. Neurological testing, data collection, and data analy-
sis were performed by a researcher blinded with respect to the treat-
ment group.
Anesthesia and Surgical Preparation
Male C57BL/6 mice (6–8 weeks, 24–26 g) were obtained from 
Charles River Laboratories (Kisslegg, Germany) and anesthetized 
in a chamber containing 4% isoflurane (Halocarbon Laboratories, 
Peachtree Corners, GA). Anesthesia was maintained by an intra-
peritoneal injection of a combination containing medetomidine (0.5 
mg/kg bodyweight), midazolam (5 mg/kg), and fentanyl (0.05 mg/
kg). The mice were intubated and mechanically ventilated with 30% 
O
2
 and 70% air (MiniVent 845; Hugo-Sachs-Elektronik, March-
Hugstetten, Germany) as described previously.20 Ventilation was 
continuously monitored using microcapnometry (MicroCapnograph 
CI240; Columbus Instruments, Columbus, OH), and end-tidal CO
2
 
was held at 35 to 45 mm Hg by adjusting the respiration parameters. 
Systemic blood pressure and arterial blood gases were monitored via 
a femoral artery catheter. Body temperature was held at 37°C using 
a feedback-controlled heating pad. After induction of SAH and a 
15-minute postinduction observation period, anesthesia was reversed 
by intraperitoneal injection of atipamezole (2.5 mg/kg), naloxone 
(1.2 mg/kg), and flumazenil (0.5 mg/kg), after which the animals 
were placed in an incubator at 33°C for 24 hours.
Measurement of Regional Cerebral Blood Flow
Regional cerebral blood flow (rCBF) was measured as described pre-
viously.21 In short, a laser Doppler probe (Perimed, Järfälla, Sweden) 
was positioned perpendicular to the skull over the ipsilateral middle 
cerebral artery territory. Laser Doppler flux was recorded continu-
ously from 10 minutes prior to 20 minutes after the induction of SAH. 
In in vivo microscopy experiments (3 hours after SAH), rCBF was 
measured after anesthesia induction and was recorded continuously 
through the observation period.
Measurement of Intracranial Pressure
Intracranial pressure (ICP) was measured using a microchip-based 
probe (Codman ICP monitor; Codman, Ascot, United Kingdom) 
placed in the epidural space over the contralateral hemisphere as 
described previously.22 ICP was recorded 10 minutes before and for 
20 minutes after the induction of SAH.
Blood Gas Analysis
Arterial blood samples were collected before SAH and at the end 
of the observation period and analyzed using a blood gas analyzer 
(Chiron Diagnostics Corporation, East Walpole, MA).
Induction of SAH
SAH was induced using the endovascular perforation technique, as 
described previously.17,21 In brief, a 5-0 filament was inserted into the 
left external carotid artery and advanced toward the circle of Willis. 
Hemorrhage was confirmed by a rapid increase in ICP with a cor-
responding decrease in rCBF. The filament was then removed, the 
external carotid artery ligated. In sham surgery, the filament was 





 receptor–specific antagonist clazosentan was kindly pro-
vided by Actelion Pharmaceuticals (Basel, Switzerland). For the 
dose-finding and chronic (neuroscore) experiments, clazosentan 
was administered intravenously in the internal jugular vein via an 
ALZET osmotic mini-pump (Durect Corporation, Cupertino, CA) 
implanted subcutaneously. In the first set of experiments (dose find-
ing; schematic drawing is given in Figure IA in the online-only Data 
Supplement), clazosentan was administered at 1, 3, 10, or 20 mg/kg 
bodyweight, and mean arterial blood pressure (MAP), rCBF, and ICP 
were monitored continuously for 180 minutes starting 15 minutes 
after successful pump implantation. Subsequent experiments evaluat-
ing post-SAH outcome for up to 72 hours (chronic group; schematic 
drawing is given in Figure IC in the online-only Data Supplement) 
were performed using 10 mg/kg clazosentan administered continu-
ously via an osmotic mini-pump beginning 30 minutes before SAH 
induction. In in vivo microscopy experiments, clazosentan was con-
tinuously administered via a femoral vein catheter over a period of 
30 minutes; cerebral microcirculation was monitored for 30 minutes 
before, during, and for 60 minutes after drug injection (a graphical 
summary is given in Figure IB in the online-only Data Supplement).
Intravital Microscopy
In vivo two-photon microscopy was performed as described previ-
ously.23,24 In brief, after induction of anesthesia and surgical prepa-
ration, a cranial window was prepared over the left middle cerebral 
artery territory (Figure IIA in the online-only Data Supplement). After 
an intravenous injection of 150 µL fluorescein isothiocyanate-dextran 
(MW 150 kDa; Sigma-Aldrich, Deisenhofen, Germany; Figure 1, 
for example image), the pial microvessels (ranging from 9.5 to ≈80 
µm in diameter, 15–30 vessel segments per animal, with at least 4 
measurements for each vessel category; n=8 mice per group) were 
visualized and subsequently categorized as either category 1 (9.5–25 
µm diameter) or category 2 (>25 µm diameter). Three hours after 
SAH, two-photon microscopy was performed; after recording base-
line values for 30 minutes, mice received an intravenous infusion of 
either clazosentan (10 mg/kg) or vehicle (phosphate-buffered saline; 
control) for 30 minutes, after which cerebral microcirculation was 
imaged for an additional 30 minutes. After an injection of fluorescein 
isothiocyanate-dextran, the cerebral microcirculation was scanned at 
10-minute intervals and analyzed offline as described previously.17,25 
Several parameters were recorded to evaluate the severity, and degree 
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of microvasospasm was recorded; specifically, vessel diameter was 
measured in a segment that was deemed to be nonspastic, and the 
severity of the spasm was assessed using a spasticity index shown in 
Figure IIB in the online-only Data Supplement (the constriction grade 
of the spastic vessel compared with a nonspastic vessel segment was 
calculated for each vessel at each time point and compared with the 
respective baseline value).
Neurological Function
Neurological outcome (n=9 mice per control group and n=8 per 
clazosentan group, 1 dropout that died within 20 minutes after SAH most 
probably because of rebleeding) was assessed by testing motor function 
(eg, the grasping reflex and the righting reflex), parameters reflecting 
general well-being (eg, bodyweight, fur grooming), and vigilance as 
described previously.21 A composite score of 0 points was assigned to 
healthy animals, and the maximum deficit score was 33 points.
Statistical Analysis
All data are presented as median±SD. All data were assumed to be 
nonparametric. For comparisons between 2 groups, we used the 
Mann–Whitney rank-sum test. Multiple groups were analyzed using 
the Kruskal–Wallis ANOVA on ranks, and repeated measurements 
were analyzed using the Friedman test. Calculations were performed 
using a standard statistical software package (SigmaPlot 13.0; Jandel 
Scientific, Erkrath, Germany). Differences between groups were 
considered significant at P<0.05. Sample size calculations were per-
formed using the following parameters: α error=0.05; β error=0.2; 
calculated SD 15% to 20% (depending on the parameter investi-
gated); and biologically relevant difference 30%.
Results
First, we continuously infused 1, 3, 10, or 20 mg/kg clazosen-
tan into the internal jugular vein of healthy C57BL/6 mice 
for 3 hours while measuring MAP (Figure 2A) and rCBF 
(Figure 2B). Although clazosentan had no effect on either 
MAP or rCBF at any dose, 20 mg/kg caused a slight decrease 
in MAP toward the end of the observation period; therefore, 
we used 10 mg/kg clazosentan for the subsequent experiments.
SAH was induced using the middle cerebral artery fila-
ment perforation model; it caused both a rapid increase in 
ICP (Figure 3A) and a rapid decrease in rCBF (Figure 3B); 
ICP remained significantly elevated until the end of the 
observation period, CBF normalized within 10 minutes. 
Sham-operated mice did not show any increase in ICP or 
decrease in cerebral blood flow (data not shown). There was 
no significant difference in either ICP or rCBF between the 
control and clazosentan groups; physiological parameters 
directly after SAH induction were within normal limits in 
both groups (Table II in the online-only Data Supplement). 
Animals were allowed to wake up afterward; 2 hours after 
SAH, mice were reanesthetized and prepared for intravital 
microscopy. After baseline recording, they were randomized 
to the clazosentan or control group. MAP was not affected by 
clazosentan treatment and remained within the physiological 
range throughout the observation period (Figure 3C). Blood 
gases measured at the end of the observation period did not 
differ between the 2 groups (Table III in the online-only Data 
Supplement). As illustrated in Figure 1, 3 hours after SAH, 
we observed a global narrowing of the arterioles and vessels, 
with a pearl string–like appearance, reflecting the presence of 
microvasospasms, consistent with previous reports.17,26 Sham-
operated mice did not exhibit any alterations of the cerebral 
Figure 1. Intravital microscopy of cerebral microvesssels. Exem-
plar in vivo microscopy image taken 3 hours after subarachnoid 
hemorrhage; note the microvascular constriction and pearl 
string‒like appearance (arrows).
Figure 2. Dose-finding experiment. Clazosentan at the indicated 
dosages or saline (control) was administered by intravenous 
infusion as shown in Figure 1, and mean arterial blood pressure 
(MAP; A) and cerebral blood flow (B) were monitored for 3 hours.
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microcirculation such as microarterial constriction or micro-
vasospasm. Clazosentan treatment had no significant effect on 
the total number of microvasospasms (Figure 4A); similarly, 
clazosentan had no significant effect on the severity of micro-
vasospasms in small or large microvessels (Figure 4B and 4C, 
respectively). Moreover, clazosentan had no significant effect 
on the diameter of nonspastic segments of vessels (Figure 5). 
Last, we examined whether pretreating mice with clazosentan 
can improve neurological outcome after SAH (Figure IC in the 
online-only Data Supplement). Consistent with our results on 
microvasospasms, we found that clazosentan did not improve 
neurological outcome assessed using a multivariate neurologi-
cal score (Figure 6).
The numeric data for all groups/experiments are provided 
in Tables IV through XIV in the online-only Data Supplement.
Figure 3. Induction of subarachnoid hemorrhage (SAH). SAH 
was successfully induced in all animals, reflected by a significant, 
rapid increase in intracranial pressure (ICP) peak (A) and decrease 
in regional cerebral blood flow (rCBF; B) at the time of middle 
cerebral artery perforation. Three hours later, mice were reanes-
thetized and prepared for in vivo microscopy (IVM); randomization 
to the treatment or clazosentan group was performed after surgi-
cal preparation and recording of baseline. C, Mean arterial blood 
pressure (MAP) was measured during IVM and was not affected 
by clazosentan infusion (baseline refers to 3 hours after SAH).
Figure 4. Clazosentan does not improve cerebral microcircula-
tion after subarachnoid hemorrhage (SAH). Time course of the 
total number of vasospasms (A) and the spasticity index in small-
diameter (B) and larger-diameter vessels (C) in mice treated with 
clazosentan or saline (control), expressed relative to baseline 
recorded before randomization to treatment at t=3 hours after SAH.
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Discussion
The CONSCIOUS-1 trial (Clazosentan to Overcome 
Neurological Ischemia and Infarction Occurring After 
Subarachnoid Hemorrhage), a large phase 2 clinical trial 
designed to investigate the role of ET
A
 receptors in post-SAH 
ischemia and outcome, reported that ET
A
 receptor inhibitor 
clazosentan significantly reduced SAH-induced angiographic 
vasospasms.12 Thus, researchers hoped that delayed vaso-
spasm—which was thought to be the key factor in delayed 
cerebral ischemia and neurological outcome—would finally 
be manageable. However, subsequent trials found that inhibit-
ing ET
A
 receptors had no beneficial effect on ischemic infarcts 
or functional outcome.13,27,28 More recent studies therefore pri-
marily focused on the early posthemorrhagic phase (ie, within 
72 hours of the SAH), which is characterized by a reduction in 
cerebral blood flow with no change in cerebral perfusion pres-
sure14,15 followed by microcirculatory dysfunction. A variety 
of mechanisms collectively referred to as early brain injury 
have been proposed to contribute to this phenomenon16,18 and 
are now considered to be the pathophysiological correlate of 
delayed ischemic changes after SAH. By directly visualizing 
the cerebral microcirculation soon after SAH, microarterio-
lar constriction (ie, microvasospasm) can be observed under 
both experimental17,29,30 and clinical26,31 conditions. To date, 
the mechanisms that underlie microvasospasm remain poorly 
understood. Our group29 and others32,33 have found evidence 
suggesting that global or local depletion of nitric oxide (NO), 
a potent vasodilator, plays a causal role in the formation of 
posthemorrhagic microcirculatory dysfunction; specifically, 
increasing NO levels causes a rapid reduction in microarte-
riolar constriction and significantly improves both mortality 
and outcome,29 demonstrating that reducing microvasospasms 
can indeed improve both structural and functional outcomes. 
As NO depletion is also a major pathophysiological feature in 
delayed-onset vasospasm,34,35 it seemed reasonable to assume 
that spasms of large and microvessels after SAH may have 
some pathophysiological similarities. ET-1 (endothelin-1) is a 
potent, long-lasting endogenous vasoconstrictor that has been 
implicated in the delayed arterial vasospasm in the circle of 
Willis.36,37 Moreover, ET-1 levels are elevated both in patients9 
and in animal models after experimental SAH.38 Although 
most clinical studies measured increased ET-1 in the cere-
brospinal fluid or plasma at relatively later time points (eg, 
>48 hours after hemorrhage), there is experimental evidence 
showing that ET-1 levels are significantly elevated as early 
as 30 minutes after the induction of SAH.8 The vasoconstric-
tive effect of ET-1 after SAH seems to be mediated primarily 
by the ET
A
 receptor subtype.39,40 Using a peptide-based ET
A
 
receptor antagonist, Clozel and Watanabe6 found that cerebral 
blood flow was significantly increased in a rat model of SAH; 
however, the antagonist was effective only when adminis-
tered intracerebroventricularly. This practical limitation was 
overcome with the introduction of the selective nonpeptide 
ET
A
 receptor inhibitor R0 61–1790, which was later named 
clazosentan; intravenous injection of clazosentan before the 
induction of SAH significantly improved post-SAH cerebral 
blood flow in both rats41 and mice.42 Moreover, clazosentan 
improved the initial widespread hypoperfusion and delayed 
the onset of vasospasm; however, clazosentan did not reduce 
ischemia or improve neurological outcome after SAH in 
Figure 5. Clazosentan does not affect the diameter of spastic 
microvessels. Vessel diameter was measured in the nonspastic 
segments of small-diameter (A) and larger-diameter (B) vessels in 
mice treated with clazosentan or saline (control), expressed rela-
tive to baseline.
Figure 6. Clazosentan does not improve neurological outcome 
after experimental subarachnoid hemorrhage (SAH). Neurological 
outcome was assessed using a multivariate neurological score 1 
day before SAH and for 3 days after SAH. Where indicated, the 
mice were treated with saline (control), 1 mg/kg clazosentan, or 
10 mg/kg clazosentan.
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clinical studies. However, as these trials were specifically 
designed to assess angiographic vasospasm at later time points 
after SAH and did not include measures to investigate early 
brain injury, it remained unclear whether a possible effect of 
ET
A
 receptor inhibition on early microcirculatory dysfunction 
may have been missed.
This is the first study to directly examine the putative role 
of ET
A
 receptors in early post-SAH changes in the cerebral 
microcirculation. We found that pharmacological inhibition 
of ET
A
 receptors had no effect on either the number or sever-
ity of microvasospasms after SAH, nor did it affect the global 
constriction of arterial microvessels. Furthermore, we found no 
significant improvement in neurological outcome after SAH. 
These results suggest that ET
A
 receptors do not likely play a 
major role in the development of microvasospasms after exper-
imentally induced SAH. Given that inhibiting ET
A
 receptors 
reduces spasms in large cerebral arteries after SAH, but has 
no apparent effect on microvessels, these results also suggest 
that large-vessel spasms and microvasospasms are mechanisti-
cally distinct phenomena; thus, findings on large cerebral ves-
sels may not necessarily apply to cerebral microvessels. This 
may be particularly relevant when attempting to relate in vitro 
results obtained from isolated vessels to in vivo results.
Microvascular constriction can occur as early as 3 hours 
after SAH, and it can last up to 72 hours or longer.17 In a previ-
ous study, we demonstrated that reduction of microarteriolar 
constriction and microvasospasm led to a significant reduction 
of posthemorrhagic brain damage and improved neurological 
outcome thereby stressing the importance of early microcircu-
latory phenomena for structural and functional outcome after 
SAH.29 We found that inhibiting ET
A
 receptors at the time of 
peak microvasospasm did not reduce the number of microvaso-
spasms, nor did it affect global microcirculatory constriction. 
In addition, clazosentan did not improve neurological function 
measured for 3 days after SAH, stressing the importance of 
early changes in the microcirculation for neurological out-
come. Our results are consistent with results obtained by others 
who found no significant effect of inhibiting ET
A
 receptors on 
microthrombosis,42–44 cell death,42,43 or endothelial nitric oxide 
synthase uncoupling.42 Therefore, we conclude that ET
A
 recep-
tors do not play a major role in the pathophysiology of early 
microvasospasms and—subsequently—early brain injury after 
SAH. Our findings may also explain the apparent failure of 
inhibiting ET
A
 receptors inhibition after SAH in a clinical trial: 
because post-SAH ischemia is caused by a perturbation in the 
microcirculation and because inhibiting ET
A
 receptors affects 
large but not small arterioles, this approach is not likely to 
improve ischemia or neurological outcome after SAH.
In our study, we used clazosentan to inhibit ET
A
 recep-
tors because its pharmacokinetics and its ability to selec-
tively and potently inhibit ET
A
 receptors have been studied 
in detail, including in rodents.45–47 Nevertheless, we cannot 
exclude the possibility that clazosentan-specific side effects 
may have counteracted a possible beneficial effect of inhib-
iting ET
A
 receptors. However, this is unlikely, given that 
clazosentan did not affect the animals’ basic physiologi-
cal parameters and we did not detect adverse events dur-
ing dose finding. Furthermore, clazosentan was applied by 
continuous intravenous infusion, thereby minimizing any 
possible effects of pharmacokinetics.
In summary, we present data suggesting that ET
A
 receptors 
do not play a major role in the development of microvaso-
spasm or microarteriolar constriction after SAH, suggesting 
that macrovasospasms and microvasospasms are mediated by 
distinct mechanisms which have far-reaching consequences 
for future treatment strategies and therapeutical approaches. 
Given that maintaining the function of the cerebral microcir-
culation is a prerequisite for improving outcome after SAH, 
additional research is needed to determine the mechanisms 
that underlie SAH-induced microvascular dysfunction.
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